MediciNova, Inc. announced topline results of its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) in patients with nonalcoholic fatty liver disease (NAFLD) and ...
Yuichi Iwaki, M.D., Ph.D. Founder, Chairman, CEO, and President MediciNova, Inc.
Welltica+ on MSN
Researchers explain the first signs of the muscle disease ALS
This video delves into the subtle, early physical changes that could signal the onset of ALS (amyotrophic lateral sclerosis).
Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat ...
Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.
In this article, we analyze recent M&A and TOB news from the perspective of a former strategy consultant. We decode not just ...
Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi ...
The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.
Isao Teshirogi, Shionogi's chief executive. Shionogi has reached a $2 billion agreement to buy Anglo-US biotech IntraBio and ...
Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to ...
Advanced MRI has revealed the first consistent brain signature of the ultra-rare neurological disorder FOSMN, showing ...
Since acquiring the global rights to edaravone, a treatment for amyotrophic lateral sclerosis (ALS), known as RADICAVA ® in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results